News|Articles|June 10, 2026

How the Chai Discovery–Eli Lilly Collaboration Could Advance the Future of AI-Driven Biologics Development

Author(s)Danielle Valletti, Assistant Editor

Chai Discovery’s collaboration with Eli Lilly highlights the growing role of AI in biologics discovery, leveraging generative AI models to accelerate design and optimization of novel therapeutic proteins and antibodies.

Artificial intelligence (AI) continues to reshape pharmaceutical research, particularly in the discovery and optimization of biologic therapies. In January 2026, Chai Discovery announced a collaboration with Eli Lilly and Company to accelerate biologics discovery by deploying advanced AI models to design novel therapeutic proteins and antibodies.¹